Pooja Bhagia - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun , Lin Shen , Manish A. Shah +22 more

Merck Sharp & Dohme.

2021 The Lancet 1394 citations

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Takashi Kojima , Manish A. Shah , Kei Muro +24 more

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phas...

2020 Journal of Clinical Oncology 1110 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,504
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-6312-7397

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.